<DOC>
	<DOCNO>NCT00822237</DOCNO>
	<brief_summary>This study test safety , tolerability , immunogenicity VARIVAX manufacture 2007 commercial Varicella-Zoster Virus ( VZV ) bulk process concomitantly administer M-M-R II healthy child .</brief_summary>
	<brief_title>Study Test Safety Immunogenicity VARIVAX ( 2007 Process ) ( Study V210-057 ) ( Completed )</brief_title>
	<detailed_description>This treatment approve sale public .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject good health base medical history Subject history measles , mumps , rubella , chickenpox , shingle Subject previously receive measles , mumps , rubella , and/or varicella vaccine either alone combination Subject history immune disorder Subject expose chickenpox/shingles , measles , mumps , rubella varicella within 4 week study start Subject receive inactivated vaccine within 14 day first dose study vaccine Subject receive live vaccine within 30 day first dose study vaccine Subject receive blood transfusion bloodderived product within 3 month receive study vaccine Subject fever within 72 hour study start</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>